Natera (NTRA) is down 6.8% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver is a continued negative reaction to Natera’s recent quarterly update, where strong revenue growth and higher full-year guidance were overshadowed by a wider-than-expected per-share loss, heavier operating spending, and an unexpected CEO transition. If this decline is occurring after the initial post-earnings selloff, it could be because investors are still repricing the stock after that mixed message.
Details:
Sources:
SEC, Natera Investor Relations, MedTech Dive
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$NTRA Insider Trading Activity
$NTRA insiders have traded $NTRA stock on the open market 327 times in the past 6 months. Of those trades, 0 have been purchases and 327 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 82 sales selling 309,915 shares for an estimated $95,336,819.
- JONATHAN SHEENA has made 0 purchases and 117 sales selling 62,142 shares for an estimated $21,074,738.
- ROELOF BOTHA has made 0 purchases and 6 sales selling 78,000 shares for an estimated $17,184,092.
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 30 sales selling 62,436 shares for an estimated $16,407,209.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 23 sales selling 54,814 shares for an estimated $14,512,417.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 38 sales selling 40,027 shares for an estimated $12,750,734.
- HERM ROSENMAN sold 16,530 shares for an estimated $4,132,500
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 15 sales selling 11,717 shares for an estimated $3,953,973.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 9 sales selling 11,944 shares for an estimated $3,727,138.
- GAIL BOXER MARCUS has made 0 purchases and 4 sales selling 11,000 shares for an estimated $2,389,328.
- ROWAN E CHAPMAN has made 0 purchases and 2 sales selling 3,099 shares for an estimated $679,636.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NTRA Hedge Fund Activity
We have seen 550 institutional investors add shares of $NTRA stock to their portfolio, and 402 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM removed 56,117,951 shares (-99.6%) from their portfolio in Q3 2026, for an estimated $23,194,110,327
- FMR LLC added 8,228,912 shares (+151.0%) to their portfolio in Q3 2026, for an estimated $3,401,091,618
- PRICE T ROWE ASSOCIATES INC /MD/ removed 3,162,981 shares (-26.0%) from their portfolio in Q2 2026, for an estimated $858,591,192
- WELLINGTON MANAGEMENT GROUP LLP removed 1,195,051 shares (-29.6%) from their portfolio in Q3 2026, for an estimated $493,926,528
- JPMORGAN CHASE & CO added 1,174,852 shares (+9.1%) to their portfolio in Q3 2026, for an estimated $485,578,080
- GOLDMAN SACHS GROUP INC added 952,921 shares (+124.2%) to their portfolio in Q2 2026, for an estimated $258,670,405
- CAPITAL WORLD INVESTORS added 930,660 shares (+61.9%) to their portfolio in Q3 2026, for an estimated $384,651,084
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$NTRA Government Contracts
We have seen $791,200 of award payments to $NTRA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- DNA TESTING: $230,000
- TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $80,400
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
$NTRA Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 15 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Baird issued a "Outperform" rating on 11/09/2026
- JP Morgan issued a "Overweight" rating on 11/06/2026
- Evercore ISI Group issued a "Outperform" rating on 11/06/2026
- BTIG issued a "Buy" rating on 10/27/2026
- Canaccord Genuity issued a "Buy" rating on 10/19/2026
- Morgan Stanley issued a "Overweight" rating on 10/13/2026
- TD Cowen issued a "Buy" rating on 10/13/2026
To track analyst ratings and price targets for $NTRA, check out Quiver Quantitative's $NTRA forecast page.
$NTRA Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 20 analysts offer price targets for $NTRA in the last 6 months, with a median target of $404.0.
Here are some recent targets:
- Catherine Ramsey from Baird set a target price of $403.0 on 11/09/2026
- Casey Woodring from JP Morgan set a target price of $405.0 on 11/06/2026
- Daniel Markowitz from Evercore ISI Group set a target price of $400.0 on 11/06/2026
- Mark Massaro from BTIG set a target price of $430.0 on 10/27/2026
- Kyle Mikson from Canaccord Genuity set a target price of $500.0 on 10/19/2026
- Tejas Savant from Morgan Stanley set a target price of $435.0 on 10/13/2026
- Dan Brennan from TD Cowen set a target price of $480.0 on 10/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.